Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (251-260 of 272) with videos related to

Pageof 28
Sort By:
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Kidney International Reports|December 18, 2023
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA NephropathyFrederick W K Tam, James Tumlin, Jonathan Barratt, et al.
JAMA|June 5, 2026
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical TrialBrendon L Neuen, Vlado Perkovic, Rajiv Agarwal, et al.
Lancet (London, England)|March 16, 2024
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International|September 24, 2021
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesBrad H Rovin, Sharon G Adler, Jonathan Barratt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 31, 2021
A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder WorkshopsSimon A Carter, Liz Lightstone, Dan Cattran, et al.
Kidney International|May 8, 2021
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular diseaseSimon A Carter, Charlotte Logeman, Martin Howell, et al.
Kidney International Reports|July 31, 2024
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases CohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International|May 25, 2019
Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular diseaseSimon A Carter, Liz Lightstone, Daniel Cattran, et al.
Kidney International Reports|November 29, 2023
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury CasesZaid K Yousif, Jejo D Koola, Etienne Macedo, et al.
Pageof 28

Showing results (251-260 of 272) with videos related to

Sort By:
Pageof 28
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Kidney International Reports|December 18, 2023
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA NephropathyFrederick W K Tam, James Tumlin, Jonathan Barratt, et al.
JAMA|June 5, 2026
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical TrialBrendon L Neuen, Vlado Perkovic, Rajiv Agarwal, et al.
Lancet (London, England)|March 16, 2024
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International|September 24, 2021
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesBrad H Rovin, Sharon G Adler, Jonathan Barratt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 31, 2021
A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder WorkshopsSimon A Carter, Liz Lightstone, Dan Cattran, et al.
Kidney International|May 8, 2021
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular diseaseSimon A Carter, Charlotte Logeman, Martin Howell, et al.
Kidney International Reports|July 31, 2024
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases CohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International|May 25, 2019
Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular diseaseSimon A Carter, Liz Lightstone, Daniel Cattran, et al.
Kidney International Reports|November 29, 2023
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury CasesZaid K Yousif, Jejo D Koola, Etienne Macedo, et al.
Pageof 28